Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
|
||
Form 20-F_X___
|
Form 40-F_______
|
|
|
||
Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
|
||
|
Yes______
|
No___X___
|
|
||
Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
|
||
|
Yes______
|
No___X___
|
|
||
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule12g3-2(b) under the Securities Exchange Act of 1934.
|
||
|
Yes______
|
No___X___
|
|
||
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):82 N/A
|
Exhibit
|
Description
|
|
|
|
|
ICON plc
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Brendan Brennan
|
Date: January 13, 2020
|
|
Brendan Brennan
Chief Financial Officer
|
DUBLIN--(BUSINESS WIRE)--January 13, 2020--ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations, today announced that Dr. Steve Cutler, CEO and Mr. Brendan Brennan, CFO of ICON plc, will present at 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020. The presentation will be webcast live from 10.30am PST. ICON’s financial guidance for the year ended December 31, 2020 will be released by press release on Tuesday, January 14, 2020 prior to the presentation and will be discussed during the presentation.
A link to the live webcast will be available via the Investor section of our website under “Events”.
About ICON plc
ICON plc is a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON operates from 99 locations in 40 countries and had approximately 14,600 employees as at September 30, 2019. Further information is available at www.iconplc.com.
This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov.
Source: ICON plc
ICON/ICLR-G
Investor Relations
+1888 381 7923
or
Jonathan Curtain
Vice President Corporate Finance and Investor Relations
+353 1 291 2000